Alpha Tau (NASDAQ: $DRTS) Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events
$DRTS is potentially just 12 patients away from FDA approval to treat Recurrent GBM!
The company has shared new trial data showing all patients are still alive, with 100% ORR, 100% Feasibility and 83.3% Complete Response!
Investor Call coming up today (November 16) at 8:30am ET
BREAKING: Israeli company Alpha Tau Medical has released updated results to their FDA brain cancer (rGBM) trials.
5 patients show NO SIGNS of the lesion after a one month MRI follow up.
SAFETY: 100% All patients treated met safety/feasibility results.
EFFICACY: 100% ORR. Complete Responses (CR) went from the initial 2/3 to 5/6. Every patient saw at least 58% reduction in tumor size. All patients are still alive.
IMPACT: While there are still 12 patients left in the FDA trial and survival duration is being monitored, it appears clear that $DRTS has achieved results thought impossible.
Targeted radiation from Alpha Tau’s platform is eliminating inoperable brain tumors.
$DRTS Price Target Raised to $22 by Piper Sandler
The firm upgrades Alpha Tau to Overweight (the strongest buy rating) ahead of the new rGBM trial data coming out this week!
A Demonstration Of The $DRTS Treatment For Brain Cancer
A significant update from the REGAIN trial for Recurrent GBM is coming within days!
Alpha Tau CEO said to follow closely
The Alpha DaRT treatment uses the existing biopsy hole to insert the alpha radiation sources directly into the tumor, destroying it from the inside while sparing the healthy tissue around it, all in a single session within minutes
Early results have shown 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile
🚨BREAKING: Patients #4 and #5 in the $DRTS Recurring GBM Trial have been Recruited and Scheduled for Treatment!
Following Alpha Tau achieving 100% local control and Complete Response in Recurring GBM, the FDA approved more patients and new sites for the completion of the trial
$DRTS CFO on their new Commercialization Deal:
“Tens or hundreds of thousands of dollars per treatment, tens of thousands of patients per year”
That’s Billions in revenue from just one indication in one country, with more to come!
חברת אלפא תאו $DRTS חתמה על הסכם שבמסגרתו היא צפויה למכור טיפולים לסרטן הערמונית בארה״ב
מדובר על עשרות אלפי מטופלים בשנה, בסכום של למעלה ממאה אלף דולר לטיפול, שהם מיליארדים בהכנסות שנתיות לחברה רק מאינדיקציה אחת במדינה אחת
Fox Business said it right: ASCO 2026 is the Super Bowl of oncology and Alpha Tau is the rising star in the game that is becoming impossible to ignore.
$DRTS CFO ahead of the several cancer trial readouts expected this year: “Last trial we read out we saw 100% complete response rate, every tumor disappeared of course, and we saw no serious side effects”
Alpha Tau $DRTS: The Isotope Sniper vs. Market Noise. Why March 2026 is the Inflection Point.
While speculative capital is currently bleeding out of ImmunityBio ($IBRX), which hit a regulatory wall after aggressive marketing triggered FDA warning letters (down 21% this week) - smart money is quietly rotating into Alpha Tau Medical ($DRTS).
This isn't just "another biotech."
This is a company that has cleared the world's toughest regulatory hurdle, yet its valuation still fails to reflect the incoming wave of commercialization.
1⃣The Tech: Why $DRTS Wins Over Tradition
Radiation therapy has historically been "carpet bombing" - effective, but devastating to the surrounding environment.
Alpha DaRT technology introduces sniper-like precision. It utilizes alpha-particle emitters (Radium-224), which possess massive kinetic energy to shred cancer DNA, but a range of less than 0.1 mm.
➡️The Core Advantage:
We can "burn out" a tumor from the inside without touching healthy tissue just a millimeter away.
More importantly for combo-therapy strategies: Alpha DaRT does not destroy the immune system (no lymphopenia), as confirmed by recent pancreatic cancer data (81% disease control rate).
This makes it the perfect partner for immunotherapies.
2⃣Japan and the Logistical "Moat"
The Japanese PMDA approval on February 24, 2026, was the ultimate De-risking Event.
Japan has the most stringent safety standards globally; their "yes" is a quality certificate for the rest of the world.
However, the real value lies in the logistics.
Radium-224 has a half-life of only 3.6 days.
Alpha Tau’s nearly completed facility in New Hampshire isn't just an investment; it’s a barrier to entry.
Competitors cannot "copy" this model overnight. In radiopharmaceuticals, he who owns the nuclear permits and the factory closest to the patient dictates the terms.
3⃣The Cold Assessment: Risks and the "Bear Case"
No research is 10/10 without addressing the threats. Investors must consider:
➡️Dilution Risk:
While the company has cash through 2027, biotechs often conduct a public offering following major news (e.g., the Q2 Glioblastoma data) to fund global roll-out. Expect volatility.
➡️Competition:
Actinium Pharmaceuticals ($ATNM) and RayzeBio (Novartis) are breathing down their necks. While DRTS has unique diffusion tech, the fight for hospital budgets will be brutal.
➡️ReSTART Trial: If the pivotal U.S. trial shows even marginally weaker results than the Japanese data, the market will likely overreact with a panic sell-off.
3⃣The $IBRX Lesson: Fundamentals > Hype
The ImmunityBio case proves that aggressive marketing without flawless FDA documentation is a recipe for disaster.
$DRTS is following the "Device" (PMA) pathway rather than the "Drug" (BLA) pathway, which historically offers a faster route to full U.S. commercialization and less bureaucratic friction regarding manufacturing changes.
4⃣Investment Strategy
➡️Entry Point:
The current consolidation in the $6.80 - $7.15 range looks like institutional accumulation.
➡️Binary Catalyst:
Glioblastoma (GBM) data in Q2 2026.
Success in brain cancer is an immediate re-rating event and makes the company a prime M&A target for giants like AstraZeneca or Novartis.
➡️Stop Loss:
A technical exit below $6.10, which would negate the institutional support thesis.
⬇️Verdict:
You are buying sniper technology at the price of a slingshot.
$DRTS is currently the most compelling risk/reward profile in the MedTech sector.
You are getting technology already validated by Japan at a pre-hype U.S. price.
🗨️Is $DRTS the sleeper MedTech play of 2026, or is the biotech sector too volatile right now?
Drop a Like ❤️ if you’re watching this space, and let me know your top pick for Q2 below! 👇
“Q2 catalysts success could drive 2-3x returns”
Dr. Elena Voss, Senior Biotech Equity Analyst, believes $DRTS is a “high-reward biotech with tangible de-risking milestones ahead.”
NEW: Alpha Tau Medical (NASDAQ: $DRTS) March 2026 Investor Presentation
Highlights:
- Upcoming catalysts
- Massive potential TAM
- FDA relationship
- Keytruda combination trial
- Manufacturing and Finances
“I’m cancer free thanks to $DRTS."
With hundreds of successfully treated patients worldwide, this FDA Breakthrough Device is a smarter way to treat cancer. Now approved in Japan with many upcoming catalysts.
״בעזרת הטיפול הזה, קיבלתי את איכות החיים המלאה שהייתה לי לפני שחליתי, מלאה אני מתכוון 100%״
לוחם השייטת לשעבר שנרפא מסרטן בזכות הטיפול של של חברת אלפא תאו $DRTS, מספר על ההחלטה ששינתה את חייו.
Citi and H.C. Wainwright raise price targets on $DRTS to $9 and $12.
Analysts say Japan’s approval validates the platform, de-risks U.S. progress, and is leading to partnership opportunities.
Upcoming catalysts include Phase 3 completion, Pancreatic and GBM trials, the Keytruda combination study, and more.
Citi raises $DRTS price target to 9$.
“The firm believes the company’s radiopharma platform is being underappreciated at current share levels.
Alpha Tau’s broader-than-expected Japan approval in head and neck cancer is leading to partnership opportunities.”
JUST IN: $DRTS to share results from first GBM patients.
Alpha Tau will hold an initial safety readout this coming quarter for the first three patients treated, followed by completion of patient recruitment for their FDA Recurrent Glioblastoma trial.